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Abstract: Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for 
dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as pos-
sible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline 
release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 recep-
tors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic pa-
tients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to 
clozapine. For patients who do respond, there is a wide (>ten-fold) range in optimal doses. Refractoriness or low sensitiv-
ity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozap-
ine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is 
lost. 
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1. INTRODUCTION 
  The first antipsychotic drug - chlorpromazine - was dis-
covered serendipitously in the early 1950s. It was soon real-
ized that, as well as antipsychotic actions, such drugs pro-
duce motor side effects reminiscent of Parkinson’s disease. 
This combination of main effect and potent motor side ef-
fects  led  to  their  being  called  “neuroleptic  drugs”.  In  the 
1960s, it started to be understood that these medications act 
by blocking receptors for the neurotransmitter dopamine. By 
the early 1980s it was known that there is more than one type 
of dopamine receptor, and today these are divided into two 
classes - the D1-class receptor (D1 and D5), and the D2-class 
(D2, and its variants, plus D3 and D4). For much of this his-
torical development, common understanding has been based 
on a number of implicit assumptions: (i) A single receptor 
type - the D2 receptor - is responsible for both the antipsy-
chotic main effect, and the motor side effects; (ii) Antipsy-
chotic  action  is  relatively  rapid,  once  the  receptors  are 
blocked, and as with  most drugs, the bigger the dose, the 
bigger, and more rapid the effects, for both the therapeutic 
and the adverse side effects. (iii) Failure of therapeutic re-
sponse  may  be  because  the  dose  is  not  enough.  All  these 
suppositions can now be challenged, but their legacy endures 
sometimes in routine prescribing practice. 
  A further important but little-explored area is the defini-
tion of individual optimal doses for the beneficial effects of  
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these drugs. Guidelines for dosage,  and dose equivalences 
between different drugs have been based on group averages 
derived from dose-finding trials. If there are large differences 
in individual sensitivity, this must mean that some patients 
are  treated  with  doses  far  exceeding  their  optimal  dose. 
Apart  from  acute  motor  side  effects,  antipsychotic  drugs 
have serious long-term side effects. With the original neuro-
leptic drugs tardive dyskinesia and related conditions emerge. 
With “second-generation”, or “atypical” antipsychotic drugs, 
these problems are less but not eliminated, and other prob-
lems  (weight  gain,  and  the  “metabolic  syndrome”)  have 
caused  increasing  concern.  In  addition,  especially  for  the 
lower potency agents in both the first- and second-generation 
families of antipsychotic drugs, sedation is a common side 
effect, with major impact on quality of life. In view of these 
problems,  definition  of  the  optimal  or  minimum-effective 
dose  for  each  patient  is  an  important,  unresolved  issue. 
Whether there is a sharp threshold dose (with no effect be-
low this dose, and full effect above it), or a region in the 
dose-response  curve  where  the  clinical  response  gradually 
increases with dose, is a difficult question  to resolve, dis-
cussed further in PART II, Sect. 3. 
  Taking  together  the  above  areas  of  unresolved  debate, 
there  is room for a much better  theoretical account of the 
action of these drugs.  The present  article  attempts  to con-
struct a framework to resolve these issues. This builds on the 
author’s earlier publications, including detailed theory of the 
phenomenology  of  psychosis  and  the  process  of  recovery 
during antipsychotic drug therapy [24,25,100,102,103]. The 
focus here is on pharmacological receptor types and related 
functions involved in actions of various classes of antipsy-
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2.  PSYCHOSIS  AS  AN  EXAGGERATION  OF  THE  
REINFORCEMENT FUNCTION OF DOPAMINE 
  Full  recovery  from  florid  psychotic  episodes  may  take 
weeks, or even months, to run its full course, although rele-
vant receptors are blocked within hours [99,103]. The psy-
chological processes occurring during this period, while not 
widely studied, have been described in various ways. Using 
the language of learning theory they have been conceived as 
an  extinction-like  process  [8].  Clinical  accounts  refer  to  a 
reduction in “behavioural impact” and “preoccupation” with 
delusional beliefs [106]. Using psychodynamic terminology 
they have been described as “working through conflicts of 
belief” [99,100,103]. A key to understanding these features 
of antipsychotic therapy is that one role of the neurotransmit-
ter dopamine is as a central “reinforcement” signal, inferred 
from earlier behavioural work on instrumental conditioning. 
This clue  led to the proposal in 1976 that psychosis  is an 
abnormal exaggeration of the reinforcement function of do-
pamine, as it applies to typically-human cognitive processes, 
especially those involved in acquiring beliefs [97,98]. 
  These processes, seen as formally similar to instrumental 
learning  as  studied  in  experimental  animals,  generate  dis-
torted  beliefs,  whose  motivational  significance  is  exagger-
ated. Antipsychotic drugs were then envisaged to slow down 
the process of formation of such abnormal beliefs, without 
erasing those  already laid down in long-term memory.  By 
overall slowing of mental activity, normal processes of resti-
tution can come into play. Patients then gradually come to 
realize which beliefs are trustworthy, and to disregard those 
which have been a symptom of an illness. These processes 
take weeks or months to reach completion. Full restitution is 
then permitted by (but is not a direct  consequence of) the 
medication. Beninger [8] developed a broadly similar con-
cept  of  psychotic  states,  approaching  the  subject  from  the 
perspective of instrumental learning theory. The concept of 
psychosis as an overactivity of the reinforcement function of 
dopamine is now becoming accepted. It has many implica-
tions for further theory-development (explored in this paper), 
a practical implication being that once the dose is big enough 
to start to be effective, the eventual benefit is as much a mat-
ter of duration of treatment as of dose. 
3.  CHALLENGES  TO  THE  “SINGLE  RECEPTOR” 
ACCOUNT ACTION OF ANTIPSYCHOTIC DRUGS 
  (i) With classical neuroleptic drugs, the beneficial effects 
and  adverse  motor  side  effects  are  closely  associated,  and 
could plausibly be attributed to actions at a single receptor 
class. However, by the early 1970s it was known that the two 
effects  could  be  dissociated:  Certain  drugs  (clozapine  and 
thioridazine),  were  known  to  be  effective  antipsychotic 
agents, but had a low tendency to produce motor side effects 
[57,143].  Subsequent  research  at  the  Janssen  laboratories, 
based on collating profiles of receptor binding, clinical ef-
fects and side effects for a variety of antipsychotic agents 
[85,86] led to the conclusion that antipsychotic agents which 
are relatively free from motor side effects often combine D2-
blocking  potency  with  antagonism  at  one  of  the  serotonin 
receptors (identified as the 5HT2a receptor). This led to the 
modern improved “atypical” antipsychotic agents - the “se-
rotonin-dopamine antagonists”, or  “SDAs”. Clozapine (but 
not thioridazine) fits this profile to some extent [96] but it is 
now clear that clozapine, and (as argued later) probably also 
thioridazine owe their distinctive clinical properties to other 
aspects of their basic pharmacology. 
  (ii) By the early 1990s PET technology had been devel-
oped to measure, in vivo, the proportion of various receptors 
occupied when patients received therapeutic doses of anti-
psychotic  drugs.  For  most  antipsychotic  drugs  (including 
most  “atypicals”), 65-70% occupancy of dopamine  D2 re-
ceptor  was  required  to  achieve  therapeutic  benefits 
[41,114,149,154]. For typical neuroleptics, higher occupancy 
(75-80%) was needed before gross motor side effects were 
produced [72,148]. The occupancy needed for a therapeutic 
response may be an overestimate, since rigorous procedures 
to establish “minimum effective doses” were not adopted in 
these studies. Nevertheless, this evidence is compatible with 
the  “single  receptor”  hypothesis  for  antipsychotic  drugs, 
which achieve different effects at the same receptor at differ-
ent occupancy thresholds. However,  at least  two drugs do 
not  fit  this  pattern.  Clozapine  [41,78],  and  (amongst  the 
newer drugs) quetiapine [78,82], can be therapeutically ef-
fective with much lower occupancy (~40%) of the D2 recep-
tor. It has been suggested [136] that the special actions of 
these drugs depend on rapid release from binding to the D2 
receptor,  but  the  theory  underlying  this  concept  has  been 
criticized [117]. It has also been suggested [138] that queti-
apine, which has  a short biological half-life, actually does 
have  transiently  high  occupancy,  this  being  sufficient  for 
therapeutic  action.  This  idea  is  still  sub  judice.  However, 
several other lines of evidence, presented later in this paper, 
indicate that quetiapine is unusual compared to other antip-
sychotic drugs, in ways compatible with a different mode of 
action. 
  These  discrepancies  mean  that  receptors  other  than,  or 
additional to the D2 receptor are important in antipsychotic 
therapy, for clozapine and perhaps for quetiapine. This con-
clusion  is  supported  by  the  fact  that,  while  classical  D2-
blocking neuroleptics increase blood prolactin levels, an ef-
fect  also  seen  during  therapy  with  some  atypical  antipsy-
chotic agents, this is not found with clozapine or quetiapine 
[27,53,75,95]. 
  (iii) If the idea is accepted that psychosis represents an 
exaggeration  of  the  reinforcement  function  of  dopamine, 
there  is  a  severe  paradox:  That  reinforcement  function, 
whether examined in behavioural terms [9,105] or in terms 
of the dopamine-mediated synaptic change underlying it [77] 
derives  from  the  actions  of  dopamine  at  D1  receptors,  or 
from the mechanisms of synthesis of cyclic adenosine mo-
nophosphate (cAMP) [10], produced by D1 receptors, and 
not (mainly) at D2 receptors; yet, for the antipsychotic ef-
fects of neuroleptic drugs, the focus has always been on the 
D2 receptor, affinity for which scales with clinical potency 
of these drugs [30,137]. It has been claimed on the basis of 
several clinical trials [33,34,73,74] that D1 antagonists lack 
antipsychotic  effects.  These  clinical  trials  are  not  rigorous 
refutation of the possibility that D1 antagonists have antipsy-
chotic effects, mainly because, in those trials, an insufficient 
number of patients survived a  long enough test period (at 
least  28  days)  to  draw  definite  conclusions  [102,103,App. 
4]). A sharp paradox remains,  if psychosis is viewed as  a 
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4.  THEORY:  THE  INDIRECT  MODE  OF  THERA-
PEUTIC  ACTION  OF  D2-BLOCKING  ANTIPSY-
CHOTIC DRUGS 
  To resolve this paradox, it has been proposed in several 
publications [101,102,103,105] that the D2-blocking agents 
act indirectly, the final common target of antipsychotic drugs 
of all  classes being the D1 receptor, or the  mechanism of 
synthesis of cAMP controlled by this receptor. This proposal 
fits evidence [94] that conditioned avoidance learning in rats 
(a test which is the best behavioural predictor of potency of 
antipsychotic agents in humans) can be attenuated in propor-
tion to the affinity for either D1 receptors (for drugs which 
have higher potency at D1 than at D2 receptors) or at D2 
receptors (for drugs whose potency is higher at D2 than at 
D1 receptors). 
  What  steps  could  intervene  between  D2  blockade,  and 
reduced D1 receptor  activation (or reduced  cAMP synthe-
sis)? Two hypotheses are depicted in Fig. (1). In early for-
mulations  [101,105],  it  was  proposed  that  in  vivo,  in  free 
moving preparations, D2 blocking agents slowed the firing 
of midbrain dopamine neurones, whose dopamine release in 
the striatum was then reduced, “unloading” critical D1 recep-
tors of their transmitter. It was known that D2 antagonists 
increased the firing rate of dopamine neurones, but that find-
ing was based almost entirely on experiments in anaesthe-
tized animals. However, single unit recording of dopamine 
neurones  in  free-moving  rats,  challenged  with  cataleptic 
doses of neuroleptic drugs, also showed increased firing, just 
as in anaesthetized preparations [B.I.Hyland, [pers com; 102: 
[Fig. (2)]). This is a decisive refutation of the original hy-
pothesis. 
  More recently, new data have emerged, which provide an 
alternative, and better account of the stages intervening be-
tween D2 blockade and antipsychotic effects. In the striatum, 
a small proportion (2-3%) of neurones are “large cholinergic 
interneurones” [35]. Their neural activity, and release of ace-
tyl  choline  (ACh)  is  controlled  (inter  alia)  by  dopamine, 
which  inhibits  these  neurones  at  D2  receptors  [55,84,135, 
144,145,156]. Hence D2-blocking agents increase the firing 
rate, and release of ACh by these neurones. This is relevant 
to  the  motor  side  effects  of  antipsychotic  agents,  because 
these  effects  can  be  alleviated  by  anticholinergic  agents. 
What are the actions at the cellular level, and the relevant 
receptors for this tonically-released ACh? There are at least 
five muscarinic receptors at which ACh might produce its 
actions [14,15] several of which (M1, M2, M4) are found in 
the  striatum.  Ultrastructural  studies  with  special  labelling 
methods [56,65] show  that  two of these (“M1” and “M4” 
receptors) are located on dendritic membranes of the princi-
pal neurones of the striatum, the medium spiny cells, a likely 
cellular target for production of both antipsychotic main ef-
fects and motor side effects of these drugs. It has been diffi-
cult to be specific about the cellular effect of these receptors, 
because few cholinergic agents are specific for one or other 
of  these  receptor  types.  Nevertheless  from  studies  using 
gene-knockout techniques in mice, cell types in which spe-
cific receptors have been expressed, or, most recently, selec-
tive  neurotoxins,  insights  into  their  different  roles  are  ap-
pearing. 
  From gene knockout mice, it is known that M2-receptor-
deficient mice no longer show tremor after administration of 
a  cholinergic  agonist  [48].  However,  this  receptor  type  is 
located mainly on axon terminals of striatal neurones other 
than  the  medium-spiny  type  [56],  probably  including  the 
cholinergic interneurones. The behavioural effects are there-
fore probably due to reduced ACh release  in the striatum, 
rather than a receptor-specific postsynaptic effect of absence 
of this receptor type. The M1 receptor is located on medium 
spiny neurones, especially within their dendritic spines [56], 
and is present in almost all such neurones [158]. This recep-
tor is known to suppress a potassium current in these neu-
rones [141], leading to increased neuronal excitability. Since 
there are no specific agonists for this receptor it has not yet 
been  possible  to  show  directly  the  behavioural  effects  of 
stimulation  of  this  receptor.  However,  it  is  known  that  in 
free-moving rats, many [20,79,110], perhaps all [102] me-
dium  spiny  neurones  increase  their  firing  rates  in  low-
dopamine  states,  characterised  behaviourally  by  akinesia. 
This  is  a  likely  effect  of  reduction  of  dendritic  potassium 
currents. Although never tested, the same increase probably 
occurs  when  akinesia  and  catalepsy  are  induced  by  D2-
















Fig. (1). Alternative hypotheses for indirect action of dopamine 
D2-receptor-blocking antipsychotic drugs. Both hypotheses pos-
tulate increased firing of striatal cholinergic interneurons, and that 
the final common target of antipsychotic drugs is reduced formation 
of cAMP. Left: Indirect action mediated by the aversive effects of 
extrapyramidal side effects (EPS). Right: Indirect action mediated 
by increased activation of striatal muscarinic M4 receptors. Mechanisms of Action of Antipsychotic Drugs  Current Neuropharmacology, 2009, Vol. 7, No. 4    305 
effects of D2-blocking agents are mediated by increased cho-
linergic stimulation of M1 receptors on medium spiny neu-
rones. The M4 receptor appears to limit cAMP synthesis, so 
that, when this receptor is activated, cAMP synthesis, stimu-
lated  in  some  other  way,  is  decreased  [115,116,118,132]. 
This  makes  M4 agonists  similar  in their  effects on  cAMP 
synthesis to D1 antagonists. An agent with putative M4 ago-
nist actions, developed by Lilly has been tested and shown to 
have predicted neurochemical effects [125]. This similarity 
is supported by results of animal behavioural tests predictive 
of antipsychotic potency in humans [1,140]. It is then pre-
dicted that in animals treated with M4 agonists, processes of 
synaptic  change,  thought  to  underlie  psychosis,  would  be 
retarded.  It  is  proposed  here  (also  [102,103])  that  D2-
blocking  antipsychotic  drugs,  by  accelerating  firing  in  the 
cholinergic interneurones, increase ACh release which acts 
at  M1 receptors,  leading  to motor side effects,  and at  M4 
receptors  to  reduce  dopamine-mediated  synaptic  potentia-
tion. In humans, the latter action sets in process the chain of 
events leading to alleviation of psychotic symptoms. 
  Other evidence supports this reasoning. Cholinergic in-
terneurones are involved in one form of synaptic change in 
the striatum -  long-term  synaptic depression [153]. In this 
case the M1 muscarinic receptor is implicated. It is predicted 
that  cholinergic  mechanisms  are  also  involved  in  another 
form of synaptic change - long-term synaptic potentiation - 
which is more relevant in the context of psychosis, and that 
the M4 receptor should be primarily involved. In monkeys, 
the acetyl cholinesterase inhibitor gallantamine inhibits psy-
chosis-like behaviour induced by d-amphetamine [2]. Older 
evidence shows that anticholinesterases, or cholinomimetics 
may be helpful in psychotic states [67,120]. New data, based 
on the traditional practice in many Pacific islands of betel-
nut chewing, suggest that actions of cholinergic alkaloids in 
betel nuts  may also be  antipsychotic [146]. Exactly which 


















Fig. (2). Effect of D2-receptor blocking drugs on firing rate and firing pattern of dopamine cells recorded in free-moving rats. A:- 
Rate-meter histogram (top panel; one-second bins) shows increased firing rate in this cell after raclopride injection at time 0 (“R”). The auto-
correlogram plots below the histogram, calculated from the 10-minute pre-drug control period (left) and the period 10-20 minutes post-drug 
(right), show irregular firing before, and enhanced bursting after injection in this cell. B:- A cell showing increased firing rate and decreased 
regularity of firing after haloperidol (“H”). C:- Relationship between baseline (pre-drug) firing rate and post-drug firing rate, calculated from 
period 10-20 minutes post-injection. Diagonal line shows line of equality (no change). D:- Relationship between baseline firing rate and the 
change in firing rate (difference between pre- and post-drug firing rates expressed as a percentage of baseline rate) induced by D2 antago-
nists. (from B.I.Hyland, personal communication, with thanks). 306    Current Neuropharmacology, 2009, Vol. 7, No. 4  R. Miller 
against psychosis, and whether any presently-available anti-
psychotic drugs (including the atypical ones and the unique 
drug clozapine) act in this way, is discussed below. 
5.  NEUROLEPTIC-RESISTANT  PSYCHOSIS,  AND 
INDIVIDUAL  DIFFERENCES  IN  NEUROLEPTIC 
SENSITIVITY 
  It has long been suspected that some psychotic patients 
do not respond to standard antipsychotic drugs, but that there 
is something special about the drug clozapine in this respect. 
In 1988 [70] it was proved conclusively that clozapine was 
therapeutically effective, when other antipsychotic medica-
tions had failed. Since then, patients who are unresponsive to 
standard medications have increasingly been regarded as a 
separate class as far as drug treatment goes. Rigorous crite-
ria,  based  on  effects  of  previous  drug  treatment,  are  now 
adopted to define this class of patient. 
  Related to this is the suspicion that the patients who do 
respond to standard medications vary greatly, one from an-
other  in  their  sensitivity  to  the  therapeutic  effects  of  the 
drugs used. In the earliest days of neuroleptic treatment the 
German  psychiatrist-neurologist  H.-J.Haase,  well  aware  of 
the unpleasant nature of the motor side effects, proposed that 
the dose of a neuroleptic which produced the least detectable 
signs of parkinsonism was the dose which produced all, or 
almost all of the therapeutic benefits [49,50]. To assess what 
he called the “neuroleptic threshold dose”, he developed a 
handwriting test, not itself a quantitative measure, although 
the  estimates  of  individual  thresholds  obtained  with  this 
method  were  quantitative.  Admittedly,  with  some  drugs, 
therapeutic benefits can be achieved without motor side ef-
fects  (see  above),  and  the  “neuroleptic  threshold”  concept 
also received criticism [142], as applied to classical neuro-
leptics.  Nevertheless  the  concept  gained  general  support 
from  Angus  and  Simpson  [5],  authors  with  experience  in 
both psychiatric and neurological evaluation. A later review 
of Haase’s handwriting test as a guide to neuroleptic doses 
including new data [83], offered some criticisms, but sup-
ported  Haase’s  concept  in  most  cases.  McEvoy  and  co-
workers [92] conducted a rigorous test of Haase’s “thresh-
old” concept, using another sensitive clinical test of motor 
function, also generally supporting the concept. 
  From such studies it was clear that the oral dose of a neu-
roleptic needed to achieve the “threshold” in the handwriting 
test  varied  greatly  between  patients.  For  the  drug  fluphe-
nazine, the range of 2-14 mg/day (mean 4.56 mg/day) was 
reported [142], and from Haase’s own work, the means and 
standard  deviations  (SD)  are  4.7±2.7  mg/day  for  the  drug 
bromperidol [51], and 19.0±8.85 mg/day for the drug drop-
eridol [52]. In the study of McEvoy and others [92] for the 
drug haloperidol, the threshold dose ranged, across 106 pa-
tients from <1 mg/d to 10 mg/day (mean 3.7±2.3), and was 
larger  for  patients  previously  treated  with  neuroleptics 
(4.3±2.4 mg/day) than for those receiving them for the first 
time (2.1±1.1 mg/day), a point of relevance in Sect. 7 (be-
low). The “coefficients of variation” (CV) for the neuroleptic 
threshold in these studies is large (45-55%, or up to 62% in 
McEvoy’s study). 
  Direct assessment of variation in individual sensitivity to 
antipsychotic effects of these drugs is difficult. Outside psy-
chiatry, individual sensitivity to many drugs is assessed by 
trying different doses in  the same patient. However, treat-
ment  of  acute  psychotic  episodes  is  often  an  emergency 
situation,  not  to  be  repeated  if  possible.  Therefore,  most 
dose-finding  clinical  trials  average  results  across  patients, 
with  loss  of  data  about  individual  sensitivity.  A  new  ap-
proach to identifying individual drug sensitivity in treating 
acute psychosis is discussed in PART II (Sect. 3). Individual 
variation in minimum dose required in relapse-free mainte-
nance treatment is also difficult to assess, because, in typical 
cases, relapse does not occur immediately on withdrawal or 
on dose reduction, but in a probabilistic fashion, sometime in 
the next year or two [39,54,58,60,69,90,111]. This principle 
also applies to atypical antipsychotic drugs [47,157]. There-
fore study design generally has involved large groups of pa-
tients, with results expressed as percentage surviving without 
relapse as a function of time after the change. Again data on 
individual sensitivity to the relapse-prevention effects of the 
drug  are  hidden  amongst  the  group  data.  The  only  viable 
approach is therefore to undertake careful longitudinal stud-
ies of each patient. A recent paper [66] did just that, not for 
typical psychosis, but in mentally-retarded adults, in relation 
to aggression and self-injurious behaviours. For haloperidol, 
across 16 patients, the minimum dose needed to prevent such 
behaviours (below which they were known to have occurred, 
and above which stable maintenance was possible) ranged 
from  0.5-18  mg/day  (6.38±6.1  mg/day);  for  4  patients  on 
chlorpromazine,  it  ranged  from  50-400  mg/day  (200±147 
mg/d); and for 11 patients on thioridazine, it ranged from 40-
250 mg/day (131±65 mg/d). CVs ranged from ~50 to ~95%. 
  It  might  be  suggested  that  individual  variation  in  re-
sponse,  and  even  non-responsiveness,  depends  on  differ-
ences in pharmacokinetics (absorption, protein binding, me-
tabolism etc) of the drug. However, blood levels of medica-
tions in refractory patients are within, or (often) well above 
the range normally found to be effective [87]. For more typi-
cal patients, who do respond to medication, the plasma con-
centration  of  haloperidol  needed  to  reach  the  “neuroleptic 
threshold”,  showed  a  spread  of  values  (4.9±2.9  ng/ml; 
CV=59%) just as wide as that for oral doses [91]. (In such 
studies haloperidol is the preferred drug, because its pharma-
cokinetics are simplest, with probably no active metabolites 
[44]). 
  Most neuroleptic drugs are extensively bound to plasma 
proteins, only unbound drug having access to the brain. If 
protein  binding  varies  between  subjects,  “plasma  level” 
would be an inaccurate guide to the effective concentration, 
to which the brain was exposed. One study [129] estimates, 
for 14 subjects, the fraction of haloperidol bound to plasma 
protein as 12.5±4.3%. Therefore, any measured plasma level 
of this drug would give a serum  level subject to  a CV of 
34%. This is less than values cited above, for the CV of the 
“neuroleptic threshold”. Plasma levels have also been used 
to predict occupancy of D2 receptors [43]. If inter-subject 
variation in the fraction of free drug in the serum played a 
part in determining individual sensitivity, it would limit ac-
curacy  of  prediction  of  occupancy  of  brain  D2  receptors. 
However, using a simple model to make predictions, there 
was a mean error of only 6.6% (95% CI: 4.28-8.98%). As-
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serum,  the  value  given  for  its  inter-subject  variance  [129] 
would lead to much larger error than this. One must con-
clude that variance in protein binding is unimportant in de-
termining individual sensitivity. There must be an additional, 
substantial source of variance, more central than the serum 
levels of free drug. 
  What could this uncontrolled variable be? One possibility 
is the number or occupancy of dopamine D2 receptors in the 
striatum. Admittedly, if it is assumed that therapeutic effects 
depend directly on action at their target receptor, it is diffi-
cult to account for the wide (>ten-fold) range of individual 
sensitivities,  and,  in  some  cases,  total  non-responsiveness. 
Many studies compare D2 receptor numbers between normal 
subjects and  those with  schizophrenia, but only one [155] 
documents  the  relationship  between  receptor  numbers  and 
neuroleptic responsiveness, the mean number being 25-30% 
lower  in  the  non-responsive  than  in  the  responsive  cases. 
“Receptor number” is however a dynamic variable, subject 
to  compensatory  change,  unless  receptor  loss  is  a  conse-
quence of cell loss; and there are few precedents for a disor-
der caused primarily by lasting excess or deficit of any re-
ceptor type, independent of cell loss. Two studies report on 
D2 receptor occupancy by antipsychotic drugs and the corre-
sponding clinical response [72,113]. Patients with the same 
D2 occupancy showed very different degrees of clinical re-
sponse. In another study [12] no correlation was found be-
tween occupancy and clinical improvement. Admittedly, the 
number of subjects in these studies was not large, and the 
measure  of  clinical  response  (the  “vertical  axis”  in  their 
plots) is not very exact, due to the difficulties of psychiatric 
rating scales. In refractory psychoses, classical neuroleptic 
drugs fail to produce a response even when D2 occupancy is 
at, or well above the levels known to be sufficient in more 
typical cases [28,46,122]. Although there is a possible con-
found in some of this evidence (see PART II, Sect. 4), these 
results suggest that non-responsiveness of such patients has 
a basis in pharmacodynamics closer to the ultimate site of 
action than the D2 receptors, and not in pharmacokinetics. 
This is compatible with the hypothesis that therapeutic action 
is  an  indirect  consequence  of  blocking  the  dopamine  D2 
receptors  (Sect.  4,  above),  the  intervening  stages  being 
highly non-linear. 
  Estimates of threshold dose, or of minimum maintenance 
dose, though variable across subjects, are generally less than 
previously-recommended  prescription  guidelines  based  on 
group averages, implying that these doses are too large. This 
view  gains  support  from  studies  of  atypical  antipsychotic 
drugs. One of these [45] used data showing that occupancy 
by dopamine of D2 receptors was  about  ~8.8%  in normal 
subjects, but higher (~15.8%) in schizophrenia patients in a 
psychotic state, due to elevated dopamine release. To reduce 
occupancy by dopamine to normal levels, it was computed 
that antipsychotic drugs should give an occupancy of ~48%. 
This is substantially lower than the 65%, said to be needed 
for therapeutic action, which would give an occupancy by 
dopamine of only 7%. It is however very similar to the occu-
pancy found empirically with doses of 10 mg/d of olanzap-
ine [12]. The computed occupancy by dopamine would be 
7.8% for olanzapine at 10 mg/d, and 5.5% for risperidone at 
6 mg/d. If occupancy by the D2 blocker reached 80% (the 
level  where  major  motor  side  effects  appear),  dopamine 
would then occupy only ~3% of receptor sites. 
6. NUMBER OF STRIATAL CHOLINERGIC INTER-
NEURONES  AS  DETERMINANTS  OF  INDIVIDUAL 
SENSITIVITY  AND  NON-RESPONSIVENESS  TO 
ANTIPSYCHOTIC DRUGS 
  From  the  foregoing  discussion  of  striatal  cholinergic 
mechanisms,  the  uncontrolled  variable  determining  neuro-
leptic  responsiveness  could  be  the  number  of  striatal  cho-
linergic interneurones, or, equivalently, the amount of ACh 
which can be released when dopaminergic inhibition of these 
interneurones  is  blocked  by  D2  antagonists.  This  variable 
could  determine  individual  sensitivity  to  antipsychotic 
agents, and, in the extreme case where there are very few 
such neurones, could lead to complete absence of a therapeu-
tic response with classical antipsychotic agents. 
  Data from a few recent studies report on the numerical 
density of striatal cholinergic interneurones in post-mortem 
brain tissue. Two studies [61,62] compare densities between 
control  subjects  and  those  with  schizophrenia.  In  various 
parts of the striatum, the CV across normal subjects ranged 
from 15-29% in the earlier study, and from 54-72% in the 
later one. These are large inter-subject variations, and, if the 
preceding  reasoning  holds  true,  would  have  an  impact  on 
individual sensitivity to actions of antipsychotic drugs. Data 
from animals support the argument: In different strains of 
mice,  sensitivity  to  neuroleptic-induced  motor  effects  (as 
measured by the  ED50% for neuroleptic drugs  to produce 
“catalepsy”) varies by a factor of more then ten [123]. The 
least-responsive  strains,  while  having  a  number  of  neuro-
chemical differences from the most-responsive strains, nota-
bly have 25-30% fewer striatal cholinergic neurones than the 
latter [31,59]. 
  Another indication of loss of cholinergic neurones is re-
duction in the numbers of dopamine D2 receptors, since such 
receptors are located on these neurones. It has been shown in 
rats that regional levels of acetylcholinesterase [89] or counts 
of striatal cholinergic neurones [68] correlate with D2 recep-
tor  numbers.  In  cytological  studies  using  the  light  micro-
scope, these neurones do label for D2-selective ligands [7], 
the  labelling being  more prominent  than for  the  more nu-
merous principal cells of the striatum [16]. One might then 
expect  that  the  least-responsive  mouse  strains  would  have 
lower striatal D2 receptors numbers than the most responsive 
strains. This was reported in one study [123] for a subregion 
of the caudate-putamen, but is not always seen [71]. D2 re-
ceptors in the striatum are found with locations on cellular 
elements additional to the cholinergic interneurones, includ-
ing the spines of principal neurones [139] and dopaminergic 
terminals.  From  studies  using  cholinergic  neurotoxins,  no 
more than 50% of D2 receptors are lost if cholinergic cells 
are  eliminated  [32,160].  There  are  no  reliable  data  on  the 
proportion of striatal D2 receptors located presynaptically on 
dopaminergic terminals. After dopamine denervation of the 
striatum, a fall in D2 receptor numbers has been reported but 
this  is not  irreversible [136]. After a kainate lesion of the 
striatum, destroying cells but not axons, 35% of the D2 re-
ceptors remain, this deficit being apparently irreversible. The 
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gic nerve terminals. Clearly there are complications which 
may prevent the prediction about D2 receptor number and 
cholinergic cell loss from being verified. Nevertheless, the 
inter-strain variation in sensitivity seen in mice is similar to 
that  seen between  individuals  in humans. A prediction for 
human patients, with some empirical support [155], is that 
lower striatal D2 receptor numbers are associated with rela-
tive or absolute neuroleptic non-responsiveness for therapy 
of psychotic states. 
7.  “NEUROLEPTIC-INDUCED  SUPERSENSITIVITY 
PSYCHOSIS” 
  In 1978 Chouinard and collaborators [23,26] suggested 
that, in some patients treated with neuroleptic drugs, the dose 
needed to control psychotic symptoms gradually rose over 
months and years of treatment, so that symptoms could break 
through, despite a previously-adequate dose, or could appear 
quickly  if  attempts  were  made  to  reduce  the  dose.  In  the 
most severe cases [22], the classical neuroleptic drugs lost 
their effectiveness completely, although patients might still 
respond well to clozapine or other non-standard medications. 
Initially [26] it was proposed that this syndrome was a con-
sequence of changes in receptor numbers. However, in 1993 
[104] it was argued that the more fundamental change was a 
reduction in the number of striatal cholinergic interneurones. 
The  proposed  pathological  process  was  that  antipsychotic 
drugs  might,  in  some  patients,  increase  neural  activity  in 
these neurones so much that they became vulnerable to cyto-
toxic processes.  The exact mechanisms of this  are beyond 
the scope of this article, but it was thought probable that they 
reflect a general vulnerability to neuronal damage, character-
istic of some people, independent of their risk of psychotic 
illnesses. From evidence and reasoning presented earlier in 
this  paper,  one  might  then  expect  that,  in  the  study  of 
McEvoy  and  co-workers  [92],  the  higher  mean  dose  to 
achieve the neuroleptic threshold in previously-treated, com-
pared to neuroleptic-naive patients may reflect neuroleptic-
induced reduction in numbers of cholinergic interneurones. 
  Since then, it has been documented that, in brains from 
persons with schizophrenia, striatal cholinergic interneurones 
are  reduced  in  numbers,  compared  to  control  subjects 
[61,62]. These studies did not link the reduction specifically 
to a previous history of neuroleptic treatment, or to neurolep-
tic non-responsiveness, but all the patients were treated ex-
tensively with antipsychotic drugs before death. Though not 
proven, it is therefore plausible to suggest that the loss of 
cholinergic neurones was a consequence of the neuroleptic 
treatment. However, it should also be made clear that some 
patients with psychotic illnesses are refractory to treatment 
with neuroleptic drugs, right from the start of their illness. 
Thus, non-responsiveness to neuroleptics, and reduced num-
bers of striatal cholinergic interneurones cannot be attributed 
solely  to  the  effect  of  antipsychotic  drugs:  Other  patients 
probably have these abnormalities ab initio. 
8.  CHOLINERGIC  INTERNEURONES  AS  “NEURO-
DYNAMIC STABILIZERS” 
  What  is  the  real  function  of  the  cholinergic  interneu-
rones? Consider the design of neural machinery for acquiring 
neural representations controlling motivationally-favourable 
executive decisions [102]. Hypothetically, this machinery is 
realized in the striatum, associated parts of the basal ganglia, 
and the other pathways by which those functions might be 
expressed. The most basic framework for this machine con-
sists of the principle neurones of the striatum, their input and 
output pathways,  and the dopaminergic reinforcement sys-
tem. Why, then, should it also be necessary to include within 
the striatum the small but influential fraction of cholinergic 
interneurones? In the book “A theory of the basal ganglia 
and their disorders” [102], a tentative answer was provided 
to this question. In the dynamic relation between the stria-
tum, other parts of the basal ganglia, the “motor thalamus” 
and the cerebral cortex, there is a very numerous set of re-
cursive connectional loops. Outputs from this system, such 
as  signals  controlling  behaviour  with  “favourable  conse-
quences”, or its equivalent for humans at the level of inter-
nalised thoughts, is capable of controlling the dopaminergic 
reinforcement system, which operates by strengthening criti-
cal afferent striatal synapses in these recursive loops. There 
is then the potential for uncontrolled positive feedback, with 
pathological consequences at neurodynamic and psychologi-
cal/behavioural levels. The symptoms of such pathology could 
be psychosis (in the cognitive domain), or abnormal involun-
tary movements - dyskinesias - (in the motor domain). (Dy-
skinesias  were  referred  to  as  “psychosis  of  movement” 
[102]).  However,  neither  psychosis  nor  dyskinesias  occur 
commonly  in  usual  circumstances  when  the  dopaminergic 
system  is  activated.  Psychosis,  when  it  does  occur  in  hu-
mans, has some other precipitating factor, such as stimulant 
drugs (which push the levels of dopamine activity well be-
yond their normal limit), or other endogenous illnesses (such 
as schizophrenia or bipolar disorder) which have many de-
fining  features  more  fundamental  than  dopamine-mediated 
psychosis. Likewise, dyskinesias are not part of the normal 
motor repertoire, even when large reinforcements are given 
in a normal fashion. They may occur, however, when dopa-
minergic  tone  is  pushed  to  extreme  levels  by  drugs  [107, 
108,131,133,134,152].  Similarly,  in  early  Parkinson’s  dis-
ease, dyskinesias are rare in response to treatment with L-
DOPA and similar drugs, but emerge as a result of additional 
changes, in advanced stages of the disease [29,109], or re-
stricted to the more severely affected side [63,76]. 
  It was suggested by Miller and Chouinard [104], that L-
DOPA-induced  dyskinesias  arise  in  Parkinson’s  disease 
when, as a complication additional to loss of midbrain do-
pamine cells, there was progressive loss of cholinergic in-
terneurones in the striatum. This was seen as a pathology in 
some ways parallel to that leading to tardive dyskinesia after 
prolonged neuroleptic treatment, or (in the cognitive domain) 
to the processes leading to neuroleptic-induced supersensi-
tivity psychosis. There is indeed evidence for loss of cho-
linergic  markers  from  the  striatum  in  some  cases  of  ad-
vanced  Parkinson’s  disease  [88,112,126].  Thus,  it  appears 
that  the  integrity  of  the  striatal  cholinergic  interneuronal 
function  is  somehow necessary for stable operation of the 
cortico-basal ganglionic system, without which uncontrolled 
positive feedback may occur. 
  A possible mechanism for this stabilizing role, involving 
striatal  cholinergic  neurones,  and  receptors  already  men-
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minergic tone is high, strengthening of excitatory synaptic 
input to medium spiny cells is favoured by either increased 
D1  activation,  or  reduced  muscarinic  M4  activation,  both 
contributing to increased cAMP formation within these cells. 
There is then a potential for positive feedback loops to de-
velop between basal ganglia and cortex. However, as men-
tioned  above,  muscarinic  M1  receptors  located  on  striatal 
medium  spiny  cells  control  conductance  in  a  potassium 
channel and  also neuronal  excitability. Activation of  these 
receptors is probably the mechanism leading to Parkinsonian 
symptoms in low-dopamine states, and in the opposite sense, 
explains the action of anticholinergic drugs used to alleviate 
motor side effects of neuroleptic drugs. When dopaminergic 
tone is elevated, cholinergic activation of the M1 receptors is 
reduced,  potassium  conductance  increases,  and  neuronal 
excitability is lowered. This has several beneficial effects: It 
reduces the tendency to motor side effects; it increases the 
signal-to-noise  ratio  of  the  impulse  traffic  in  the  medium 
spiny neurones; and it also reduces the tendency to develop-
ment of unwanted positive feedback loops, manifest as psy-
chosis or dyskinesia. That dyskinesias are nevertheless me-
diated by extreme reduction of cholinergic tone is shown by 
the fact that they can be alleviated using anticholinesterases 
[19]. At least one can say that the range of stable operation, 
from low to high levels of dopamine tone, is increased, com-
pared to that obtaining in the basic cellular framework of the 
striatum where there are no cholinergic neurones. However, 
with these neurones, stable function of the cortico-basal gan-
glionic system can occur without problems, in a much wider 
set of circumstances than in the basic framework by itself. 
  Even with a normal compliment of cholinergic interneu-
rones, animals and humans may sometimes display patholo-
gies.  Rat  strains  are  known  which  can  display  catalepsy, 
even with no pharmacological challenge [81], which is then 
exacerbated by cholinergic drugs, and reduced by atropine. 
While its neural basis in not well studied, it appears to in-
volve  the  striatum  [80,119].  The  vulnerability  to  this  dys-
function appears to have, in part, a genetic basis [93], and it 
would be interesting to know if this trait is associated with 
heightened  sensitivity  to  neuroleptic-induced  catalepsy,  or 
increased level of striatal cholinergic markers or cholinergic 
interneurones. At the other extreme, in humans, underlying 
abnormalities  elsewhere  in  the  nervous  system  [103],  can 
lead to such excesses of dopaminergic tone that episodes of 
florid psychosis occur, again with no pharmacological trig-
ger, as in schizophrenia. 
  This reasoning leads to a prediction: If cholinergic neu-
rones are lost, there will be an enhanced tendency to an un-
usual form of psychosis, or to dyskinesia, in high-dopamine 
states. Evidence mentioned above fits this expectation, with 
regard to dyskinesias. In Parkinson’s disease, treatment with 
dopamine  agonists does not usually lead  to psychosis, but 
may  do  so  more  commonly  as  the  disease  advances  [42]. 
These pathologies should not be controllable by D2 antago-
nists (whose efficacy has now been lost or reduced, along 
with the cholinergic interneurones), but will be controllable 
by drugs which act more directly on the final common target 
for antipsychotic drugs of all classes, namely the D1 dopa-
mine receptor or the M4 muscarinic receptor. Are there any 
such drugs? 
9. ACTIONS OF CLOZAPINE 
  Table 1 shows, for various antipsychotic drugs, affinities 
(Ki’s) for the D1 and D2 dopamine receptors, and for the M1 
and M4 muscarinic receptors, as well as ED50% values for 
these drugs as M4 agonists. Most antipsychotic drugs (not 
tabulated) have much higher affinities for D2 than D1 recep-
tors,  but  for  some  (clozapine,  thioridazine,  fluperlapine, 
chlorprothixene) the respective affinities are not very differ-
ent, and for a few (clozapine, one of the enantiomers of thio- 
ridazine,  fluperlapine),  affinities  for  the  D1  receptor  are 
somewhat higher than those for the D2 receptor. Potentially 
then, these drugs might owe their action to D1 antagonism, 
or  to  intracellular  consequences  of  this,  namely  decreased 
cAMP  synthesis,  upon  which  dopamine-mediated  synaptic 
change depends. However the data on affinities for M4 re-
ceptors lead to another conclusion: For clozapine, the affin-
ity for the M4 receptor is higher than for either D1 or D2 
receptors.  Clozapine  appears to be an  agonist, or a partial 
agonist at M4 receptors [18,159], but not a pure antagonist. 
Consequently, it can be proposed that the distinctive action 
of  clozapine  is  based  on  its  stimulation  of  M4  receptors, 
leading to reduction of cAMP formation, and reduction of 
dopamine-mediated  synaptic  potentiation,  and,  at  the  psy-
chological or behavioural level, reduction of reinforcement 
processes. Since it acts more directly on the ultimate target 
than the D2-blocking antipsychotic drugs, it does not require 
the  mediating  stage  of  the  cholinergic  interneurones.  It  is 
therefore effective in those cases where, either ab initio, or 
as a result of prior neuroleptic treatment, these neurones are 
reduced in number, and there is insufficient capacity for ACh 
release to  activate  M4 receptors (and limit  cAMP produc-
tion,  as  the  usual  response  to  D2-blocking  antipsychotic 
drugs). The reason why clozapine has antipsychotic effects, 
but does not cause motor side effects is then that its pattern 
of  action  at  the  different  muscarinic  receptors  on  medium 
spiny  neurones  is  different  from  that  of  endogenously-
released acetyl choline. Likewise, anticholinergic drugs can 
be used  to reduce motor  side effects without stopping the 
therapeutic effect of classical neuroleptic drugs because they 
block actions of endogenous ACh at M1 receptors, but not at 
M4 receptors. (Most such drugs have higher affinity at M1 
than at M4 muscarinic receptors [13]). 
  In Sect. 8 (above), it was suggested that drugs which di-
rectly reduce activation of the substrate for synaptic potentia-
tion in the striatum should be effective in limiting both dy-
skinesias and psychosis triggered by dopamine agonists, in 
advanced  stages  of  Parkinson’s  disease.  Clozapine  fulfils 
both these predictions: It alleviates L-DOPA-induced dyski-
nesias,  without  exacerbating  the  underlying  condition,  in 
regular  treatment [11], under test  conditions (apomorphine 
challenge: [36]), and in a randomised double-blind trial [37]. 
From reasoning developed here, this would be expected of a 
drug  with  M4  agonist,  and  M1  antagonist  properties.  The 
decline  of  symptoms  is  progressive  over  several  weeks 
[121], similar to that achieved with clozapine for psychosis, 
supporting  the  model  developed  here.  When  L-DOPA  or 
similar drugs produce psychosis in Parkinson’s disease, clo-
zapine is also effective treatment (see: review of ~200 cases 
[6];  also  [40,124,151])  without  exacerbating  parkinsonian 
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atypical  antipsychotics  [38]  depends  on  use  of  low  doses, 
although the dose needed to alleviate psychosis depends on 
its  severity  [130].  Presumably  at  higher  doses,  the  D2-
blocking potential of clozapine comes into play, thereby in-
ducing remaining cholinergic interneurones to increase ACh 
release,  and  exacerbate  parkinsonian  symptoms.  As  with 
therapy for psychoses of other origins, and L-DOPA-induced 
dyskinesias, improvement takes some weeks to reach com-
pletion [150]. It has also been noted that for some patients, 
even  the  cardinal  symptoms  of  Parkinson’s  disease  may 
benefit from clozapine [6], a result which might arise from 
direct antagonism at muscarinic M1 receptors. (continued, in 
PART II). 
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